What it is
Abaloparatide is a man-made version of a protein related to parathyroid hormone (PTHrP). It is a bone-building medicine for osteoporosis.
Like teriparatide, it stimulates new bone formation when given once a day, but it acts on the PTH receptor in a slightly different way.
US regulatory status
FDA-approved (Tymlos) for postmenopausal women with osteoporosis at high risk for fracture (2017) and for men with osteoporosis at high risk for fracture (2022). Its earlier boxed warning about bone cancer in rats was removed in 2021.
What the research shows
The ACTIVE trial showed abaloparatide reduced new spine fractures and other fractures compared with placebo in postmenopausal women. A separate trial showed increased bone density in men.
How it is given
Daily subcutaneous injection (pen)
Commonly reported side effects
- Dizziness
- Nausea
- Headache
- Fast heartbeat (palpitations)
- Higher calcium in urine
- Dizziness when standing up
Questions to ask your provider
- Is abaloparatide or teriparatide a better fit for me?
- What should I do if I feel dizzy after a dose?
- What is the plan after I finish this treatment?
Informational only. We are not doctors. PepSteady does not give medical advice, diagnose, or recommend doses, and we do not sell peptides. Always follow your licensed healthcare provider and pharmacist.